UBS initiated coverage of Inventiva (IVA) with a Neutral rating and $3 price target The firm thinks the company’s pan-PPAR agonist lanifibranor, currently in Phase 3 for metabolic dysfunction-associated steatohepatitis with fibrosis stage 2 or 3, has shown “promising” Phase 2 data and as an oral could take a piece of the large MASH market. However, with Phase 3 data expected in the second half of 2026, UBS sees the next two years as an execution period for Inventiva.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IVA:
- Inventiva’s Strategic Moves at Upcoming General Meeting
- Inventiva Gains Positive Nod for Lanifibranor Trial
- Inventiva announces DMC recommendation to continue NATiV3 trial as is
- Inventiva’s 2024 Interim Financial Highlights and Prospects
- Inventiva price target lowered to $13 from $14 at H.C. Wainwright
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
